Regulatory authorisation is a critical milestone, but it does not automatically translate into patient access. Developers must also anticipate EU and national Health Technology Assessment (HTA) requirements and prepare for country-specific pricing, reimbursement and market access pathways. These considerations increasingly influence clinical development and launch planning well before approval.

The key interface between regulatory, HTA and market access lies in practical strategic choices: how the target population is defined, which comparators are relevant, which endpoints matter, how mature the evidence basis is, and how submission and launch sequences are planned.

For regulatory professionals, whose day-to-day focus is primarily on regulatory strategy and procedures, a clearer understanding of these interfaces can help connect regulatory planning with downstream HTA, pricing and market access requirements. Shared terminology and practical trigger points can support timely cross-functional input, better-aligned clinical development and a smoother transition from market authorisation to national market access and commercialisation.

This whitepaper is a practical guide to integrating regulatory, HTA and market access planning in Europe from development to patient access.